{"product_id":"blco-pestle-analysis","title":"(BLCO) Bausch + Lomb Corporation PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bausch + Lomb Corporation PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces affecting the company and why they matter for strategy and investment. The page includes a real preview\/sample of the report so you can judge style and depth; purchase the full version to receive the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS FDA oversight of eye health products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s contact lenses, eye drops, prescription ophthalmics, and surgical devices all need FDA clearance or approval, so any review delay can push launches across its 3 business segments. FDA post-market surveillance also raises recall risk, which can hit sales and trust fast. The agency’s labeling, quality-system, and manufacturing rules shape every product line, from development to plant controls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reimbursement in major markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn major markets, cataract surgery, glaucoma care, and prescription eye drugs depend on public and private reimbursement, so payer rules shape demand for Bausch + Lomb Corporation. In the U.S., Medicare Part B usually covers 80% of approved outpatient eye care after the deductible, but national health systems in Europe can cap prices and slow premium lens and surgical tech adoption. Reimbursement shifts can also move sales between branded, generic, and procedural products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-border trade and tariff exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb operates from Canada and sells across the U.S., Europe, and Asia, so cross-border trade risk stays high. A 25% tariff or customs delay can lift the landed cost of lenses, pharmaceuticals, and surgical tools, which pressures margins and service times. That makes supply-chain routing and dual sourcing a key 2025-2026 priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health policy on vision care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic health policy matters for Bausch + Lomb Corporation because screening programs for cataracts, glaucoma, and dry eye lift diagnosis and treatment volumes. The World Health Organization says at least 2.2 billion people live with near or distance vision impairment, so national eye-care campaigns can widen the addressable market fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore screening means more diagnosed patients.\u003c\/li\u003e\n\u003cli\u003eAging-care policy boosts core demand.\u003c\/li\u003e\n\u003cli\u003eEye-health programs support product uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePolitical stability in key sales regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation depends on stable rules in the US, Canada, Europe, and Asia-Pacific, where most hospital and distributor decisions are made. In 2025, the World Bank’s Political Stability and Absence of Violence score stayed below 0.0 for many large markets, so even small shocks can slow product registrations, delay tenders, and hit hospital capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eUnstable politics can delay sales approvals.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDistributor checks and hospital buys can slow.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCapital spending falls when policy risk rises.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEye-Care Policy Could Lift Bausch + Lomb Demand Despite Global Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation faces political risk from FDA oversight, payer rules, and trade policy across the US, Europe, and Asia. WHO says 2.2 billion people live with near or distance vision loss, so public eye-care policy can lift demand fast.\u003c\/p\u003e\n\u003cp\u003eIn 2025, World Bank political stability scores stayed below 0.0 in many large markets, which can delay approvals, tenders, and hospital buys.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVision loss\u003c\/td\u003e\n\u003ctd\u003e2.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part B\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces shape Bausch + Lomb Corporation’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise PESTLE snapshot for Bausch + Lomb that quickly highlights external risks and opportunities, saving time in planning and reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources—industry reports, government data, and benchmarks—to fast-verify Bausch + Lomb assumptions and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal demand tied to aging populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal aging supports Bausch + Lomb Corporation’s demand because cataracts, glaucoma, and dry eye become more common with age. The UN says 1 in 6 people worldwide will be over 65 by 2050, up from 1 in 11 in 2019, which points to a larger long-term patient pool. That should lift demand for cataract surgery products, glaucoma care, contact lenses, and dry-eye treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation in materials and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflation in plastics, sterile packaging, freight, and labor can squeeze Bausch + Lomb Corporation fast, especially when U.S. CPI still ran at 3.4% in 2024. Price hikes are hard in contact lenses, eye drops, and OTC eye care because rivals can match or undercut quickly. Margin pressure usually hits consumer health and lower-priced generics first, where volume matters more than pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s revenue and costs span multiple currencies, including USD and CAD, so foreign-exchange swings can move reported sales, operating profit, and inventory values. This matters more because the company manufactures and distributes globally, which leaves margin and working-capital results exposed when local currencies weaken or strengthen against the U.S. dollar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConsumer spending on discretionary eye care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsumer spending on discretionary eye care is under pressure when households juggle daily disposable lenses, premium care products, and OTC eye drops against tighter budgets. In 2025, U.S. consumer sentiment stayed near the low 70s on the University of Michigan index, and that often pushes buyers toward lower-cost lenses or longer replacement cycles. Economic slowdowns can also delay upgrades in vision care, which hurts premium mix for Bausch + Lomb Corporation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak sentiment favors cheaper alternatives.\u003c\/li\u003e\n\u003cli\u003eReplacement cycles can stretch longer.\u003c\/li\u003e\n\u003cli\u003eUpgrade demand drops in downturns.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare provider capital budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare provider capital budgets shape demand for Bausch + Lomb Corporation surgical tools and intraocular lens systems, because hospitals and ambulatory surgery centers buy them from finite capex pools. With the Federal Reserve target range still 4.25% to 4.50% in mid-2025, higher financing costs can delay equipment refreshes and slow new-suite builds. In tighter markets, service contracts and higher use of installed systems matter more than new hardware sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital spending drives premium lens and surgery-system sales.\u003c\/li\u003e\n\u003cli\u003eHigher rates can delay purchases.\u003c\/li\u003e\n\u003cli\u003eService revenue gets more important.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb: Aging Demand Supports Growth, But Inflation Pressures Linger\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation benefits from aging demand, but 2025–26 cost pressure stays real: UN says 1 in 6 people will be 65+ by 2050, while U.S. CPI was 3.4% in 2024. FX swings and weak consumer spending can still hit reported sales and lens volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e1 in 6 by 2050\u003c\/td\u003e\n\u003ctd\u003eHigher eye-care demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation\u003c\/td\u003e\n\u003ctd\u003eU.S. CPI 3.4% in 2024\u003c\/td\u003e\n\u003ctd\u003eMargin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRates\u003c\/td\u003e\n\u003ctd\u003eFed 4.25%–4.50% in mid-2025\u003c\/td\u003e\n\u003ctd\u003eSlower capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eBausch + Lomb Corporation PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Bausch + Lomb PESTLE analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use, with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal rise in myopia and digital eye strain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMore screen time is lifting demand for contact lenses, dry-eye relief, and corrective care at Bausch + Lomb Corporation. Myopia is already affecting about 36% of the world’s population, and studies project 50% by 2050, with faster growth in urban youth. That keeps recurring demand strong across consumer and clinical eye-care products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowing awareness of eye health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGrowing awareness of eye health is lifting demand for Bausch + Lomb Corporation’s products, as more consumers now recognize cataracts, glaucoma, allergies, and dry eye earlier. The WHO says at least 2.2 billion people live with near or distance vision impairment, and about 1 billion cases are preventable or untreated, so education can drive earlier care and product use. Awareness campaigns also boost referrals and diagnosis rates, which helps move patients into treatment faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for convenience in lens wear\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaily disposable lenses fit users who want hygiene, simplicity, and less time spent on care; in mature contact-lens markets, convenience often drives the buy. Bausch + Lomb benefits from this shift because high-frequency replacement lifts demand for 1-day lenses and matching care products. The company reported about $4.8 billion in annual revenue, so even small mix gains in disposables can move sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAging patients seeking preserved independence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder adults want to stay mobile and independent, so demand stays strong for cataract surgery, therapeutic lenses, and glaucoma care. The WHO says at least 2.2 billion people had near or distance vision impairment in 2025, and cataracts still drive a large share of treatable loss, supporting Bausch + Lomb Corporation’s core eye-care market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder patients value independence.\u003c\/li\u003e\n\u003cli\u003eCataract and glaucoma care fit that need.\u003c\/li\u003e\n\u003cli\u003eSafe, effective treatment supports demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrust in clinically proven brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and surgeons still favor trusted, clinically proven brands in vision care because eye treatment is personal and low tolerance for error. Bausch + Lomb Corporation’s long presence and broad range of lenses, surgical tools, and eye-care products support repeat use, since consistency and availability help reduce switching risk. In eye surgery, reputation matters because outcomes are visible and decisions are often made on prior clinical evidence and peer use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrust lowers switching in sensitive care\u003c\/li\u003e\n\u003cli\u003eClinical proof supports surgeon choice\u003c\/li\u003e\n\u003cli\u003eWide availability helps repeat use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Poised as Global Vision Care Demand Rises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUrban screen use, aging, and rising eye-health awareness keep demand for Bausch + Lomb Corporation’s lenses and therapies strong. Myopia affects about 36% of the world and could reach 50% by 2050. The WHO says 2.2 billion people live with near or distance vision impairment, including about 1 billion preventable or untreated cases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyopia\u003c\/td\u003e\n\u003ctd\u003e36% now; 50% by 2050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVision loss\u003c\/td\u003e\n\u003ctd\u003e2.2B people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUntreated\u003c\/td\u003e\n\u003ctd\u003eAbout 1B cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium intraocular lens innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePremium intraocular lens innovation helps Bausch + Lomb improve post-cataract vision and stand out in a crowded market. New optics and easier delivery systems can lift surgeon adoption, especially as cataract surgery volume keeps rising worldwide, with over 28 million procedures each year. Better lens performance can also support higher-value premium sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital manufacturing and quality systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s sterile lens and device plants need tight digital control, because even small process drift can trigger recalls or FDA issues. In fiscal 2024, the Company reported $4.8 billion in net sales, so automation, process analytics, and end-to-end traceability matter for high-volume output across sites. Strong digital quality systems help cut defect risk and keep lots consistent.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR and D in ophthalmic pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation depends on R and D because prescription eye treatments need repeated stability and efficacy testing before filing. Drug development is slow: only about 1 in 10 candidates reaches approval, so technical skill and regulatory-ready data are a real moat. That makes research capability a high barrier to entry for both proprietary and generic lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConnected surgical equipment and workflow tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eModern cataract and retinal surgery now relies on integrated platforms, real-time imaging, and data-enabled workflow tools. In the U.S., about 4 million cataract surgeries a year push centers to favor systems that cut setup time, improve precision, and keep surgeon control tight. For Bausch + Lomb Corporation, digital compatibility can shape buying choices as much as device specs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated tools can lift procedure speed.\u003c\/li\u003e\n\u003cli\u003ePrecision features support surgeon control.\u003c\/li\u003e\n\u003cli\u003eDigital fit can sway center purchases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because surgery centers want fewer handoffs, smoother data flow, and lower room delays. Devices that connect cleanly with imaging and planning software are more likely to win repeat use, especially in high-volume cataract suites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConsumer tech shaping self-care behavior\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsumer tech is reshaping self-care for Bausch + Lomb Corporation: patients now research eye drops and lens care on mobile, then buy through online retail. That pushes product discovery into digital channels, where reviews, search, and content drive choice. The result is a wider marketing reach, but also tougher conversion work, because informed buyers compare price, convenience, and trust fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMobile search drives product discovery.\u003c\/li\u003e\n\u003cli\u003eOnline retail lifts purchase access.\u003c\/li\u003e\n\u003cli\u003eDigital trust shapes conversion rates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTech Advantage Fuels Bausch + Lomb’s Premium Lens Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTechnology is a key edge for Bausch + Lomb Corporation in premium lenses, digital surgery tools, and connected manufacturing. Cataract volume tops 28 million cases a year worldwide, and about 4 million in the U.S., so software fit and precision matter. Strong automation, traceability, and R and D help protect quality and support premium sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 net sales\u003c\/td\u003e\n\u003ctd\u003e$4.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal cataract surgeries\u003c\/td\u003e\n\u003ctd\u003e28 million+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cataract surgeries\u003c\/td\u003e\n\u003ctd\u003e4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical device and drug approval rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation faces strict approval and labeling rules in the U.S., EU, and other major markets. Contact lenses, prescription drugs, and surgical devices each move through separate paths such as 510(k), PMA, and NDA review, so one delay can hit multiple product lines. In 2025, this compliance risk can add launch delays, recall work, and higher remediation costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct liability exposure in eye care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEye health products can trigger costly claims if a lens, surgery, or drug causes harm, and Bausch + Lomb Corporation faces that risk across contacts, implants, and eye medicines. In 2025, FDA adverse-event reporting and post-market surveillance remained central to proving safety, since even a small defect can lead to recalls and lawsuits. Strong insurance, tight batch records, and fast complaint tracking are essential shields.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData privacy requirements for customer and patient data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation must keep digital marketing, e-commerce, and patient support data within GDPR and local privacy rules. GDPR penalties can reach €20 million or 4% of global annual revenue, whichever is higher.\u003c\/p\u003e\n\u003cp\u003eThat matters because customer and patient records often include sensitive health data, which gets stricter handling and storage rules. A breach can trigger fines, lawsuits, and trust loss that can hit sales fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and intellectual property protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBausch + Lomb Corporation depends on patents and trade-secret protection for lens, drug, and surgical device designs, and that IP helps defend pricing power. In 2025, Company Name reported about $4.8 billion in net sales, so any loss of exclusivity can hit revenue fast. When patents expire, lower-cost rivals can enter with generic or copycat products, putting margin and launch timing under pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIP supports pricing and launch exclusivity.\u003c\/li\u003e\n\u003cli\u003ePatent expiry can speed generic entry.\u003c\/li\u003e\n\u003cli\u003eProtected designs matter across all segments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eQuality and recall obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal medical device rules make Bausch + Lomb Corporation’s quality system a legal risk gate: complaint handling, lot traceability, and correction reports must be tight, or a defect can trigger field actions, recalls, or import holds. In the U.S., device corrections and removals are generally reportable within 10 working days, so response speed matters as much as product quality.\u003c\/p\u003e\n\u003cp\u003eThe legal load is high because even a small manufacturing fault can reach patients fast and force regulator action across markets. That means Bausch + Lomb Corporation has to tie compliance to daily operations, not just audits, or one weak batch can turn into a recall cost, lost sales, and delayed shipments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eComplaint handling must be fast and documented\u003c\/li\u003e\n\u003cli\u003eTraceability cuts recall scope and cost\u003c\/li\u003e\n\u003cli\u003eDefects can trigger field actions or import bans\u003c\/li\u003e\n\u003cli\u003eQuality failures quickly become legal failures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Faces Rising Legal Risk from FDA, GDPR, and IP Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation faces heavy legal pressure from FDA, EU MDR, GDPR, and patent law. In 2025, $4.8 billion net sales made IP and recall risk material, while GDPR fines can reach €20 million or 4% of global revenue. Fast reporting, traceability, and data controls help limit lawsuits, delays, and import holds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal risk\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy\u003c\/td\u003e\n\u003ctd\u003e€20 million or 4% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales base\u003c\/td\u003e\n\u003ctd\u003e$4.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall timing\u003c\/td\u003e\n\u003ctd\u003e10 working days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use plastics in contact lenses and packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDaily disposable lenses and blister packs add to plastic waste, and Bausch + Lomb reported about $4.8 billion in 2025 net sales, so packaging changes can matter at scale. Regulators and buyers are pushing for recyclable, lower-impact materials, and that pressure can shape brand reputation and procurement choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy and water use in sterile manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation’s sterile eye-care plants need tight air control, frequent cleaning, and heavy quality checks, so energy and water use stay high. In 2025, this matters more as utilities and compliance costs rise across regulated manufacturing. Efficiency upgrades in HVAC, recirculating water systems, and clean-in-place cycles can cut both cost and footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply-chain emissions from global distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBausch + Lomb Corporation ships eye-care products across continents and healthcare channels, so air and ocean freight can lift Scope 3 emissions fast. Freight transport drives about 8% of global CO2, and shipping is under sharper scrutiny from customers and investors. Carbon reporting is now a procurement filter, so lower-emission logistics can help protect bids and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related disruption risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClimate shocks can hit Bausch + Lomb Corporation’s plants and logistics hard: NOAA’s 2025 Atlantic outlook called for 13-19 named storms, 6-10 hurricanes, and 3-5 major hurricanes, raising outage and transport risk. Temperature-sensitive eye care products and sterile materials need tight storage and cold-chain control, so backup power, alternate carriers, and dual-site inventory are key. Business continuity planning matters because even short delays can disrupt patient supply.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStorms can stop output and shipping\u003c\/li\u003e\n\u003cli\u003eHeat can break storage conditions\u003c\/li\u003e\n\u003cli\u003eBackup plans protect patient supply\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eResilient warehousing and route redundancy reduce spoilage and missed deliveries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG expectations from investors and hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare buyers and capital markets now screen sustainability as part of procurement and credit risk. Healthcare produces about 4.4% of global net emissions, so Bausch + Lomb Corporation faces pressure on waste, sourcing, and disclosure to protect access with hospitals and investors.\u003c\/p\u003e\n\u003cp\u003eThat matters because ESG signals now shape enterprise trust, not just compliance. Clear emissions reporting, lower packaging waste, and ethical supply chains can support commercial wins and investor confidence at the same time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals now factor ESG into vendor reviews\u003c\/li\u003e\n\u003cli\u003eWaste cuts can support buying decisions\u003c\/li\u003e\n\u003cli\u003eEthical sourcing helps reduce reputation risk\u003c\/li\u003e\n\u003cli\u003eDisclosure strengthens investor confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBausch + Lomb Faces Rising Climate and ESG Pressure in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvironmental pressure on Bausch + Lomb Corporation is rising in 2025: about $4.8 billion in net sales means even small packaging cuts can move waste and cost. Sterile eye-care plants also use more energy and water, so HVAC, cleaning, and water reuse are key levers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$4.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStorm risk\u003c\/td\u003e\n\u003ctd\u003e13-19 named storms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight CO2\u003c\/td\u003e\n\u003ctd\u003e~8% global CO2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eClimate shocks can disrupt storage and shipping, while ESG screening now affects hospital bids and investor trust. Lower-emission logistics and recyclable packaging help protect access and margin.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234119491849,"sku":"blco-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/blco-pestle-analysis.webp?v=1785713177","url":"https:\/\/dcfanalyst.com\/products\/blco-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}